WO2007028969A3 - Composes - Google Patents

Composes Download PDF

Info

Publication number
WO2007028969A3
WO2007028969A3 PCT/GB2006/003273 GB2006003273W WO2007028969A3 WO 2007028969 A3 WO2007028969 A3 WO 2007028969A3 GB 2006003273 W GB2006003273 W GB 2006003273W WO 2007028969 A3 WO2007028969 A3 WO 2007028969A3
Authority
WO
WIPO (PCT)
Prior art keywords
akap
molecules
binding
anchoring disruption
pka
Prior art date
Application number
PCT/GB2006/003273
Other languages
English (en)
Other versions
WO2007028969A2 (fr
Inventor
Cathrine R Carlson
Birgitte Lygren
Kjetil Tasken
Enno Klussmann
Walter Rosenthal
Original Assignee
Univ Oslo
Jones Elizabeth Louise
Cathrine R Carlson
Birgitte Lygren
Kjetil Tasken
Enno Klussmann
Walter Rosenthal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oslo, Jones Elizabeth Louise, Cathrine R Carlson, Birgitte Lygren, Kjetil Tasken, Enno Klussmann, Walter Rosenthal filed Critical Univ Oslo
Priority to EP06779293A priority Critical patent/EP1928896A2/fr
Priority to CA002621272A priority patent/CA2621272A1/fr
Publication of WO2007028969A2 publication Critical patent/WO2007028969A2/fr
Publication of WO2007028969A3 publication Critical patent/WO2007028969A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des molécules qui modifient la liaison entre l'AKAP 18d et la phosphodiestérase 4D ou l'AKAP 18d et le phospholambane, ainsi que leur utilisation pour modifier l'activation, médiée par la PKA de type II, de SERCA2 dans une cellule, par exemple afin de soulager une maladie cardiovasculaire. De préférence, lesdites molécules comprennent le motif RRASTIE. L'invention concerne également des molécules telles que celles imitant la liaison de l'AKAP 18d à la PKA qui permettent une phosporylation améliorée du PLB.
PCT/GB2006/003273 2005-09-05 2006-09-05 Composes WO2007028969A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06779293A EP1928896A2 (fr) 2005-09-05 2006-09-05 Molecules de perturbation de l'ancrage
CA002621272A CA2621272A1 (fr) 2005-09-05 2006-09-05 Composes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0518027A GB0518027D0 (en) 2005-09-05 2005-09-05 Compounds
GB0518027.8 2005-09-05

Publications (2)

Publication Number Publication Date
WO2007028969A2 WO2007028969A2 (fr) 2007-03-15
WO2007028969A3 true WO2007028969A3 (fr) 2007-08-09

Family

ID=35220864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003273 WO2007028969A2 (fr) 2005-09-05 2006-09-05 Composes

Country Status (4)

Country Link
EP (1) EP1928896A2 (fr)
CA (1) CA2621272A1 (fr)
GB (1) GB0518027D0 (fr)
WO (1) WO2007028969A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2142571A4 (fr) * 2007-05-02 2010-05-05 Intrexon Corp Ligands pp1
AU2008346801A1 (en) 2007-12-31 2009-07-16 Nanocor Therapeutics, Inc. RNA interference for the treatment of heart failure
GB201208775D0 (en) 2012-05-18 2012-07-04 Uni I Oslo Chemical compounds
GB201320506D0 (en) 2013-11-26 2014-01-01 Uni I Oslo Cyclic amino compounds for the use in the treatment of cardiac disorders
CN114632147B (zh) * 2021-11-09 2024-04-30 南京大学 人类受试者心肌病的治疗

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048809A1 (fr) * 1997-04-29 1998-11-05 Lauras As Utilisation d'agents immunomodulateurs
US6011013A (en) * 1997-06-20 2000-01-04 Oregon Health Sciences University Contraceptive compositions and methods
WO2000025804A2 (fr) * 1998-11-02 2000-05-11 The Regents Of The University Of California Procede destine a inhiber l'action du phospholamban dans le traitement des cardiopathies et de l'insuffisance cardiaque
US6538022B1 (en) * 1997-09-24 2003-03-25 Orion Corporation Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors)
WO2005035003A2 (fr) * 2003-09-22 2005-04-21 Dihedron Corporation Compositions et procedes destines a augmenter l'efficacite d'un medicament
WO2006032909A2 (fr) * 2004-09-24 2006-03-30 The University Of Oslo Inhibiteurs
WO2006032923A2 (fr) * 2004-09-24 2006-03-30 University Of Oslo Inhibiteurs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048809A1 (fr) * 1997-04-29 1998-11-05 Lauras As Utilisation d'agents immunomodulateurs
US6011013A (en) * 1997-06-20 2000-01-04 Oregon Health Sciences University Contraceptive compositions and methods
US6538022B1 (en) * 1997-09-24 2003-03-25 Orion Corporation Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors)
WO2000025804A2 (fr) * 1998-11-02 2000-05-11 The Regents Of The University Of California Procede destine a inhiber l'action du phospholamban dans le traitement des cardiopathies et de l'insuffisance cardiaque
WO2005035003A2 (fr) * 2003-09-22 2005-04-21 Dihedron Corporation Compositions et procedes destines a augmenter l'efficacite d'un medicament
WO2006032909A2 (fr) * 2004-09-24 2006-03-30 The University Of Oslo Inhibiteurs
WO2006032923A2 (fr) * 2004-09-24 2006-03-30 University Of Oslo Inhibiteurs

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALTO N M ET AL: "Bioinformatic design of A-kinase anchoring protein-in silico: A potent and selective peptide antagonist of type II protein kinase A anchoring", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 8, 15 April 2003 (2003-04-15), pages 4445 - 4450, XP002375233, ISSN: 0027-8424 *
BURNS-HAMURO L L ET AL: "DESIGNING ISOFORM-SPECIFIC PEPTIDE DISRUPTORS OF PROTEIN KINASE A LOCALIZATION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 7, 1 April 2003 (2003-04-01), pages 4072 - 4077, XP002369142, ISSN: 0027-8424 *
HE H ET AL: "EFFECTS OF MUTANT AND ANTISENSE RNA OF PHOSPHOLAMBAN ON SR CA2+-ATPASE ACTIVITY AND CARDIAC MYOCYTE CONTRACTILITY", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 100, no. 9, 1999, pages 974 - 980, XP000907563, ISSN: 0009-7322 *
SIMMERMAN H K B, ET AL.: "SEQUENCE ANALYSIS OF PHOSPHOLAMBAN", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 261, no. 28, 1986, pages 13333 - 13341, XP002419823 *
TASKEN K A, ET AL.: "PHOSPHODIESTERASE 4D AND PROTEIN KINASE A TYPE II CONSTITUTE A SIGNALING UNIT IN THE CENTROSOMAL AREA", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 25, 22 June 2001 (2001-06-22), XP002436737 *
TOYOFUKU T ET AL: "Amino acids Glu2 to Ile18 in the cytoplasmic domain of phospholamban are essential for functional association with the Ca2+-ATPase of sarcoplasmic reticulum", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 269, no. 4, 28 January 1994 (1994-01-28), pages 3088 - 3094, XP002139384, ISSN: 0021-9258 *
WILLOUGHBY D, ET AL.: "AN ANCHORED PKA AND PDE4 COMPLEX REGULATES SUBPLASMALEMMAL CAMP DYNAMICS", THE EMBO JOURNAL, vol. 25, no. 10, 27 April 2006 (2006-04-27), XP002436738 *

Also Published As

Publication number Publication date
WO2007028969A2 (fr) 2007-03-15
EP1928896A2 (fr) 2008-06-11
GB0518027D0 (en) 2005-10-12
CA2621272A1 (fr) 2007-03-15

Similar Documents

Publication Publication Date Title
IL223477A (en) Pharmaceutical preparation containing modified enzyme uricase
IL184526A0 (en) Substituted aminomethylene sulphonamides, production and use thereof as medicaments
WO2009043353A3 (fr) Oligonucléotides micromir
HK1115815A1 (en) Modified proteases that inhibit complement activation
ZA200709451B (en) Catalyst manufacture
GB0510514D0 (en) Steam reforming
WO2007028969A3 (fr) Composes
GB0508740D0 (en) Steam reforming
IL196866A (en) Erythropoietin compounds, pharmaceuticals containing them and their uses
WO2006125781A3 (fr) Nouveaux anilides salicyliques substitues par haloalcoxy
WO2008077488A3 (fr) Préparation pelliculaire comestible, au goût de coca
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
WO2007127830A3 (fr) Dep2 et ses utilisations dans le trouble dépressif majeur et d'autres troubles associés
GB2434894B8 (en) Triangular asynchronous replication.
GB0618226D0 (en) Improvements in or relating to snack products
GB0505290D0 (en) Reforming catalyst
Berg Kunskapsformer:-såsom dem efterfrågas i historieprov
Sipos A comparative research on the folk music of Turkic people
Hammond Rebus Book—19 American Studies
TH91762B (th) ที่เย็บกระดาษ
BRPI0404837B1 (pt) disposição construtiva introduzida em articulação de peneiras de reservatório de produto.
AU2005901609A0 (en) Sales prompt technology
TH104309B (th) มือจับรถจักรยานยนต์
TH101117B (th) กระดาน
TH90965B (th) เครื่องเล่นแผ่นดิสก์

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2621272

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006779293

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006779293

Country of ref document: EP